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Vitamin D and hypertension
Abstract
High blood pressure is very prevalent worldwide, as well as vitamin D
deficiency. There are several observation data that support the concept that
vitamin D is involved in pathogenesis of hypertension. Also some clinical
date demonstrate positive effect of vitamin D therapy on hypertension. In
this review epidemiological date will be presented and biological mecha-
nism of vitamin D effect on blood pressure will be explained.
INTRODUCTION
High blood pressure, i.e. hypertension is very prevalent worldwide.Its prevalence in Europe is about 40% of the adult population. In
Croatia it is 37.5%, while in the United States it is even less – about 20%
(1). According to some epidemiological studies, it is estimated that
more than 1 billion people worldwide could have arterial hypertension.
Hypertension is a major risk factor for renal, cerebrovascular and car-
diovascular disease. Therefore, it is one of the most pressing health
problems in the world. Another pandemic is vitamin D insufficiency.
Almost 50% of the world’s population is affected by vitamin D insuffi-
ciency (2). In last ten years, several observation studies have supported
the concept that vitamin D is involved in the pathogenesis of arterial
hypertension. In addition, there are experimental in vitro and in vivo
data that support this thesis.
Almost two hundreds years ago, the relationship between rickets
and a lack of exposure to sunlight was observed. At the beginning of last
century the fat-soluble antirachitic substance in fish liver oil was dis-
covered. In 1922, the treatment of rickets through exposure to UV light
was introduced in clinical practice. Nine years later ergocalciferol, i.e.
vitamin D, was discovered and five years after that 7-dehydrochole-
streol. During the 1960s, 25-hydroxyvitamin D, 1.25 dihydroxychole-
calciferol and vitamin D receptors were discovered (2, 3).
There has been increased interest in vitamin D in the past decade. In
addition to its well-known role in maintaining an adequate level of se-
rum calcium, phosphorus, parathyroid hormone and normal bone me-
tabolism, there is evidence that vitamin D has a biological effect on
more than mineral metabolism (3).
Vitamin D is named a »vitamin« like vitamin A or C because of its
exogenous source, but without a doubt it is hormone.
In this review we will briefly discuss vitamin D metabolism, the epi-
demiological data on vitamin D insufficiency and hypertension, the
possible biological mechanism of vitamin D deficiency and hyperten-
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tamin D as antihypertensive drug. We will use the fol-
lowing nomenclature: vitamin D for cholecalciferol or
ergocalciferol, calcidol for 25-hydroxyvitamin D, calci-
triol for 1.25 dihydroxycholecalciferol, and vitamin D
analogs for paricalcitol – the only one registered in our
country. In rest of the world, more analogs are used, e.g.
maxacalcitol, doxercalciferol.
Vitamin D metabolism
Vitamin D is a secosteroid that is made in the skin by
the action of sunlight, or much less frequently, ingested
through diet. During ultraviolet B radiation, 7-dehydro-
cholesterol (provitamin D) is converted to previtamin D,
which is converted into vitamin D. Vitamin D is very
rarely found in food. It can be found in fish like salmon
or in fish oils. In some countries foods like milk or bread
products are fortified with vitamin D, but it is not an im-
portant source of vitamin D. In the liver vitamin D is
converted by the enzyme cytochrome 450 into calcidol.
This conversion is under low metabolic control. Calcidol
is biologically inert but it is used to determine vitamin D
status because it has a long half-life, is easily measured,
and there is good correlation between the level of calcidol
and some diseases. Despite some controversy, vitamin D
insufficiency might be defined as a calcidol level less than
25 nmol/L, deficiency between 25 to 75 nmol/L and an
optimal level more than 75 nmol/L. There are many rea-
sons for vitamin D deficiency or insufficiency: skin pig-
mentation, aging, obesity, lack of sun exposure, chronic
disease, particularly chronic kidney disease, latitude of
residence etc. (2, 3, 4).
In the kidney, calcidol is metabolized by the enzyme
1a-hydroxylase (CYP27B1) to calcitriol, an active me-
tabolite of vitamin D. The production of calcitriol is very
tightly controlled by calcium and phosphorus levels, by
parathyroid hormone and fibroblast growth factor 23.
Another enzyme in the kidney, 24-hydroxylase (CYP24),
catabolizes calcidol and calcitriol into biologically inac-
tive calcitroic acid (2, 3).
Calcitriol acts by activating the vitamin D receptor
(VDR), which binds together with transcription factor
RXR in specific regions of DNA (VDREs, vitamin D re-
sponse elements) (5). Vitamin D receptors are widely
distributed. In addition to tissue and organs involved in
mineral and bone metabolism, VDRs are found in vascu-
lar smooth muscle, endothelium, the heart, brain, skin,
pancreas, macrophages etc. Moreover, some cells like
macrophages or vascular cells express 1a-hydroxylase,
i.e. the possibility of converting calcidol into calcitriol.
This extra renal calcitriol is not tightly controlled and the
calcitriol produced in these cells have local, autocrine or
paracrine effect. The distribution of VDRs and the local
production of calcitriol demonstrate that vitamin D is a
pluripotent hormone involved not only in calcium ho-
meostasis and bone metabolism. Today, there is much
data that vitamin D deficiency or insufficiency can cause
bone disease, malignancies, metabolic and immunologi-
cal diseases, and cardiovascular disease and hypertension
(2, 3, 4).
Vitamin D and hypertension:
epidemiological data
In the last twenty years, several cross-sectional studies
and only a few prospective studies have been conducted
in an attempt to correlate vitamin D levels with blood
pressure (6, 7). One of the largest studies was the third
National Health and Nutrition Examination Survey
(NHANES III). It is a representative study of the non-
-institutionalized US population. More than 12,000 pa-
tients were included in this cross-sectional observation
study between 1988 and 1994. A significant inverse corre-
lation between blood pressure and pulse pressure and vi-
tamin D level, i.e. calcidol was observed (8). In subgroup
analyses when age was included in the analysis, an in-
verse association between calcidol and blood pressure
was discovered, but it was not statistically significant. In
other analyses of NHANES III an increased prevalence
of hypertension in patients with low calcidol level was
observed, i.e. the prevalence of hypertension in adults in
the US was 30 % higher in the lowest quartile compared
to the highest quartile of calcidol level (9). In two other
large cross-sectional studies in Europe, the German Na-
tional Interview and Examination Survey with 4,030
participants and the 1958 British Birth Cohort with more
than 6,810 participants, a reduced level of calcidol was
observed (6). Using data from the 2003–2006 National
Health and Nutrition Examination Survey a low level of
calcidol and a high level of PTH were independently as-
sociated with high blood pressure. In fact, among more
than 5,000 participants not taking any antihypertensive
medication, systolic and diastolic blood pressure decrea-
sed linearly across quintiles of serum calcidol and in-
creased linearly across quintiles of serum PTH. Even
more similar results were observed for prehypertension
(systolic blood pressure between 120–140 mmHg and di-
astolic 80–90 mmHg) (10, 11). Recently, Burgaz A and
colleagues published a meta-analysis of blood calcidol
concentration and hypertension. In the analysis 18 stud-
ies were (14 cross-sectional, 4 prospective) included with
a total of 78,028 participants. The pooled odds ratio of
hypertension was 0.73 [95% confidence interval (CI)
0.63–0.84] for the highest versus the lowest category of
blood calcidol level. In a dose response meta-analysis, the
odds ratio for a 40 nmol/L increment in blood calcidol
level was 0.84 (95% CI 0.78–0.9). Without a doubt the
conclusion from this meta-analysis is that calcidol level is
inversely associated with hypertension (12).
Inverse correlation between calcidol levels and hyper-
tension rates was confirmed also in a cross-sectional
study by Bhandari SK et al. (13). From more than 31000
patients aged 18 years and older, 2722 were included in
analysis. The overall prevalence of hypertension was 24%.
Hypertension rates were 52%, 41%, 27% and 20% in
calcidol quartiles < 15 ng/mL, 15 to 29 ng/mL, 30 to 39
ng/mL ans > 40 ng/mLm, respectively (P < 0,001). This
study demonstrates increased rates of hypertension in
patients with lower levels of calcidol starting at levels <
40 ng/mL.
300 Period biol, Vol 113, No 3, 2011.
D. Pavlovi} et al. Vitamin D and hypertension
There are studies showing no relationship between
calcidol level and hypertension. The majority of these
studies were with a smaller sample size; in some hyper-
tension was self-reported, in others studies the vitamin D
level was estimated from a semi-quantitative food fre-
quency questionnaire (6, 7).
Despite these contradictory findings, it could be con-
cluded from majority cross-sectional studies that an in-
verse relationship between calcidol levels and blood pres-
sure exists.
Biological links between vitamin D and
blood pressure
The renin-angiotensin-aldosterone system (RAAS) is
a main regulator of blood pressure and plays a critical
role in the regulation of volume and electrolyte homeo-
stasis. Increased activation of RAAS is associated with
hypertension. It is well known that renin is produced in
juxtaglomerular cells of the kidney and that it stimulates
angiotensin II and aldosterone production. Their in-
creased production elevates blood pressure by vasocon-
striction and water retention. Experimental evidence shows
that calcitriol inhibits renin synthesis in the kidney. In a
very good study Li et al. demonstrated that vitamin D,
i.e. calcitriol, is a potent inhibitor of renin synthesis (14).
They showed that renin expression and plasma angio-
tensin II production is increased in VDR receptor-null
mice, leading to hypertension, cardiac hypertrophy and
increased water intake. In wild mice, i.e. mice with intact
VDR receptors, the inhibition of calcitriol synthesis also
led to increase in renin expression, whereas calcitriol in-
jection led to renin suppression. Kong et al. have demon-
strated that this action of calcitriol on juxtaglomerular
cells, i.e. inhibition of renin expression, is independent of
calcium and PTH (15). Moreover, Zhou et al. in a few
experimental studies have demonstrated that defect in
the 1a-hydroxylase gene, i.e. local production of cal-
citriol in some cells led to hypertension, left ventricular
hypertrophy and systolic dysfunction (16). Tomaschitz A
et al. evaluated the concentration of plasma renin, angio-
tensin 2 and calcidol and calcitriol in a large cohort of pa-
tients (LURIC study) (17). In 3,296 subjects a steady in-
crease of plasma renin concentration across a declining
concentration of calcidol or calcitriol was observed. They
concluded that in humans a lower level of calcidol or
calcitriol is related to the upregulation of RAAS.
Obviously, there are enough results showing negative
relationship between calcidol or calcitriol levels and RAAS
activity.
There are also other mechanisms involved in the rela-
tionship between blood pressure and vitamin D. Second-
ary hyperparathyroidism, commonly seen in vitamin D
deficiency, could be the reason for hypertension. The
mechanism is not completely clear, but it is a well known
association that high PTH levels affect vascular smooth
muscle cells and increase vascular stiffness and promotes
atherosclerosis. This is very often seen in patients with
chronic kidney disease (6).
Another mechanism is the effect of vitamin D on cell
of the vessel. These cells express the VDR and 1a-hy-
droxylase activity. Vitamin D deficiency is associated with
endothelial dysfunction and could promote increased and
accelerated atherosclerosis and systolic hypertension (7).
Finally, vitamin D deficiency is connected with obe-
sity, metabolic syndrome and insulin resistance. All of
these are related to hypertension (7).
Vitamin D as antihypertensive drug
Unfortunately, at this time not enough studies have
been conducted to investigate the effect of calcidol of
calcitriol as an antihypertensive agent. In a small trial
Pfeiffer et al. demonstrated greater systolic blood pres-
sure reduction in the vitamin D plus calcium group ver-
sus only the calcium group (p=0.02) (18). Calcitriol as a
single i.v. dose significantly decreased systolic and dia-
stolic pressure 2h after administration in a small group of
dialysis patients. Such changes were not observed in pa-
tients with essential hypertension or healthy volunteers
(6). In a pilot feasibility study Judd E. et al. have demon-
strated that blood pressure could be reduced with cal-
citriol (19). Nine hypertensive subjects were randomized
to receive standard antihypertensive therapy in addition
to placebo, vitamin D or calcitriol. Only seven subjects
completed the study. Subjects on calcitriol therapy had a
significant decrease in systolic blood pressure compared
to a placebo. Interestingly, one week after discontinua-
tion of calcitriol therapy, systolic blood pressure returned
to pre-treatment levels.
These studies are by no means very promising but for
our every day clinical practice we need more date before
about vitamin D as antihypertensive agent.
CONCLUSION
Clinical and epidemiological studies support a possi-
ble relationship between vitamin D and hypertension.
There are some plausible biological mechanisms. Treat-
ment of patients with hypertension is still a challenge for
physicians (20). Patients with hypertension and vitamin
D deficiency could benefit from vitamin D supplemen-
tation or calcitriol treatment, particularly patients with
chronic kidney disease (21). Undoubtedly, we need more
large prospective studies.
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